Catabasis Pharmaceuticals Receives $39,600,000 Series A Funding

  • Feed Type
  • Date
  • Company Name
    Catabasis Pharmaceuticals
  • Mailing Address
    161 1st St. Cambridge, MA 02142
  • Company Description
    At Catabasis we are dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. We have assembled a team of highly motivated and experienced scientists who are committed to improving the lives of patients.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from the financing will be used to advance Catabasis’ lead program targeting type 2 diabetes, and to further the development of the company’s proprietary platform technology in additional inflammatory and metabolic diseases.
  • M&A Terms
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    MedImmune Ventures
  • Venture Investor
    Advanced Technology Ventures

Trending on Xconomy